Please wait while the transcript is being prepared...
0:00
Hello, my name is Sam Nalle,
I'm a postdoctoral fellow
at Genentech,
and I'll be discussing
therapeutic targeting
of the intestinal barrier
in inflammatory bowel disease
and graft-versus-host disease.
0:14
In this lecture I will compare
and contrast inflammatory
bowel disease,
IBD, and graft-versus-host
disease, GVHD.
I'll take a detailed look
at the intestinal barrier
in IBD and GVHD
and I will discuss
therapeutic targeting
of the intestinal barrier
in IBD and GVHD.
The goal of this lecture
is to understand
the biological basis for
rational therapeutic targeting
of the intestinal barrier
in IBD and GVHD.
0:41
Starting with inflammatory
bowel disease,
IBD is comprised
of Crohn's disease
and ulcerative colitis.
Ulcerative colitis
involves only the colon
whereas Crohn's disease
can affect
the entire
gastrointestinal tract.
Symptoms include
malabsorption, nausea,
bloody or mucoid diarrhea,
and weight loss.
Etiology involves
a combination of genetic
and environmental factors,
and IBD is more prevalent
in developed countries
in North America and Europe.
1:08
I'll give the histology
of Crohn's disease
for some more detailed
description of IBD.
Inactive IBD is characterized
by crypt
architectural distortion,
fibrosis,
or epithelial metaplasia,
but no active
inflammatory infiltrates
such as neutrophils
or eosinophils.
Mild activity is characterized
by rare intraepithelial
neutrophils or eosinophils,
and increased numbers
of neutrophils or eosinophils
within the lamina propria.
Moderate activity contains
frequent intraepithelial
neutrophils or eosinophils,
lamina propria distortion,
and markedly increased
numbers of neutrophils
or eosinophils
within the lamina propria.
Finally, severe activity
is characterized
by numerous crypt abscesses,
erosions or ulcerations
and focal sheets
of neutrophils or eosinophils
within the lamina propria.
